Aprea Therapeutics Inc (APRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -10,144 | -7,172 | -3,933 | -12,959 | -10,064 |
| Depreciation Amortization | 16 | 11 | 5 | 22 | 17 |
| Accounts payable and accrued liabilities | -716 | -162 | -72 | -314 | -516 |
| Other Working Capital | -261 | 63 | 126 | -1,055 | -347 |
| Other Operating Activity | 1,171 | 498 | 242 | 749 | 864 |
| Operating Cash Flow | $-9,933 | $-6,762 | $-3,631 | $-13,557 | $-10,046 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | N/A | -16 | -16 |
| Investing Cash Flow | $N/A | $0 | $N/A | $-16 | $-16 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 834 | 459 | N/A | 16,140 | 16,000 |
| Other Financing Activity | -36 | -18 | 56 | -1,319 | -1,312 |
| Financing Cash Flow | $799 | $441 | $56 | $14,822 | $14,688 |
| Exchange Rate Effect | 3 | 4 | 1 | -7 | 17 |
| Beginning Cash Position | 22,890 | 22,890 | 22,890 | 21,648 | 21,648 |
| End Cash Position | 13,759 | 16,573 | 19,316 | 22,890 | 26,291 |
| Net Cash Flow | $-9,131 | $-6,317 | $-3,574 | $1,243 | $4,644 |
| Free Cash Flow | |||||
| Operating Cash Flow | -9,933 | -6,762 | -3,631 | -13,557 | -10,046 |
| Capital Expenditure | N/A | 0 | N/A | -16 | -16 |
| Free Cash Flow | -9,933 | -6,762 | -3,631 | -13,572 | -10,061 |